Volume 13 Supplement 1

Challenges in malaria research: Core science and innovation

Open Access

Development of a pediatric formulation for treatment of P. falciparum malaria: Coartem® (artemether-lumefantrine) Dispersible

  • Quique Bassat1,
  • Bernhards Ogutu2,
  • Abdoulaye DJimde3,
  • Kirstin Stricker4 and
  • Kamal Hamed5
Malaria Journal201413(Suppl 1):P7

https://doi.org/10.1186/1475-2875-13-S1-P7

Published: 22 September 2014

Background

Pediatric artemisinin-based combination therapy formulations have the potential to improve the effectiveness and accuracy of dosing in young children. Coartem® (artemether-lumefantrine; AL) Dispersible was developed and launched in partnership with the Medicines for Malaria Venture for the treatment of uncomplicated Plasmodium falciparum malaria and is the first pediatric antimalarial to receive Swissmedic approval and meet WHO specifications for use in infants and children ≥5 kg.

Materials and methods

PubMed, Ovid and clinical trial registry databases were explored for publications on AL dispersible formulation in children with acute uncomplicated P. falciparum malaria, and 11 publications (6 original and 5 review articles) involving 674 infants and children were identified.

Results

In a palatability study, sweet tasting cherry was the preferred flavor by children for AL dispersible. Pharmacokinetic profile of AL dispersible was comparable to AL crushed tablets. Efficacy and safety of dispersible formulation versus crushed tablet was evaluated in a large, randomized, multicenter study in 5 sub-Saharan African countries. Efficacy and acceptability of AL dispersible were also compared to dihydroartemisinin-piperaquine (DP) pediatric in another open-label, randomized study in Kenya. A total of 674 children were randomized in both studies to receive AL dispersible with a mean age of 38.5 months, body temperature of 38.1°C and parasite density 41,974/μl. PCR-corrected cure rate was 97.8% at day 28 and 96.4% at day 42; similar to AL crushed tablets and DP in respective studies. PCR-corrected cure rate at day 28 was not related to food intake, although consumption of milk/low fat meal increased lumefantrine bioavailability compared to no food. Efficacy of AL dispersible was comparable in children with different body weights. Median parasite and fever clearance times were 34.3 and 7.9 hours, respectively. The safety profile of AL dispersible was similar to that of crushed tablets. Acceptability of AL dispersible was significantly better than DP pediatric (ease of use: P = 0.007; taste of medicine: P = 0.001).

Conclusions

AL dispersible was specifically tailored for the pediatric population and offers a convenient formulation with efficacy and safety similar to that of standard crushed AL tablets.

Authors’ Affiliations

(1)
Barcelona Centre for International Health Research (CRESIB), Hospital Clínic, Universitat de Barcelona
(2)
Centre for Clinical Research, Kenya Medical Research Institute
(3)
Malaria Research and Training Center, University of Science, Techniques and Technologies of Bamako
(4)
Novartis Pharma AG
(5)
Novartis Pharmaceuticals Corporation

Copyright

© Bassat et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Advertisement